Akero, 89bio disclose public offerings; BioAge drops Phase 2 obesity drugnews2025-01-28T14:53:04+00:00January 28th, 2025|Endpoints News|
Allakos restructures after Phase 1 failure; AB2 inks deal with Nippon Shinyakunews2025-01-27T15:25:04+00:00January 27th, 2025|Endpoints News|
Boehringer merges cancer vaccine and oncolytic virus teams; Dantari sells off assetsnews2025-01-24T15:16:32+00:00January 24th, 2025|Endpoints News|
FDA delays decision on Stealth’s Barth syndrome drug; TargetRx raises $50Mnews2025-01-23T15:43:35+00:00January 23rd, 2025|Endpoints News|
Shanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc’s $200M offeringnews2025-01-22T15:33:23+00:00January 22nd, 2025|Endpoints News|
FDA puts Atara’s INDs on hold after rejection; Ascletis’ safety data for obesity pillnews2025-01-21T15:22:39+00:00January 21st, 2025|Endpoints News|
WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeuticsnews2025-01-17T15:54:20+00:00January 17th, 2025|Endpoints News|
Boehringer’s schizophrenia asset fails Phase 3; GSK buys organoid biotechnews2025-01-16T15:08:38+00:00January 16th, 2025|Endpoints News|
Hinge Bio’s $30M raise; Keros reports additional issues in Phase 2 PAH trialnews2025-01-15T15:33:05+00:00January 15th, 2025|Endpoints News|
Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loannews2025-01-14T16:18:49+00:00January 14th, 2025|Endpoints News|
